CYTARABINE

Generic: CYTARABINE

HospiraManufacturer
INTRATHECAL, INTRAVENOUS, SUBCUTANEOUSRoute
CYTARABINEActive Substance
1990-06-04Original Approval

CYTARABINE is FDA application ANDA071868, sponsored by HOSPIRA. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.

Recalls

Top Reported Reactions

1
FEBRILE NEUTROPENIA
7,784 reports
2
OFF LABEL USE
5,221 reports
3
PYREXIA
4,270 reports
4
NEUTROPENIA
3,745 reports
5
DRUG INEFFECTIVE
3,207 reports
6
THROMBOCYTOPENIA
3,005 reports
7
SEPSIS
2,990 reports
8
DISEASE PROGRESSION
2,800 reports
9
MYELOSUPPRESSION
2,421 reports
10
PNEUMONIA
2,391 reports